Need Help With This Product?
Our specialists are here to help you find the best product for your application.
iCell Cardiomyocytes, 01434
Product Overview
Heart disease encompasses a wide range of conditions that can be a result of genetics, physiologic, and metabolic disorders as well as adverse drug reactions. The availability of human cell models that could be used to interrogate these various factors would have a profound impact on the effort to find new medicines and cures for heart disease. Derived from induced pluripotent stem cells (iPSCs), iCell® Cardiomyocytes from FUJIFILM Cellular Dynamics, Inc. (FCDI), enable a wide range of applications spanning disease research, drug discovery, safety and toxicity testing, and regenerative medicine.
- Industry Standard With the most peer-reviewed publications and supported application protocols, iCell Cardiomyocytes are the in vitro model of choice.
- Reproducible Research High purity and rigorous quality control ensure the same performance and reproducible results with every batch of iCell Cardiomyocytes.
- Human Relevance iCell Cardiomyocytes recapitulate healthy human cardiac biology and function and express relevant targets and pathways for heart disease research.
- Diverse Availability iCell Cardiomyocytes are now available from two backgrounds with no known disease-related genotypes: donors 01434 and 11713. Also available are cardiomyocytes generated from diseased backgrounds and engineered genotypes, including MyCell® Cardiomyocytes (R403Q), a model of hypertrophic cardiomyopathy derived from donor 01178 with genotype MYH7 R403Q.
Components:
Our regular business hours are 9:00am to 5:00pm Central Time (USA)
Need Help With This Product?
Our specialists are here to help you find the best product for your application.
Our regular business hours are 9:00am to 5:00pm Central Time (USA)
Technical Docs
PROTOCOLS
Application Notes
Applying Transfection Technologies to Create Novel Screening Models - iCell Cardiac Products
Application Notes
Assaying Caspase Activity & Apoptosis
Application Notes
Assaying Cell Viability
Application Notes
Assaying Cytotoxicity
Application Notes
Assaying Mitochondrial Membrane Potential
Application Protocols
Dissociating Cardiomyocytes by Enzymatic Treatment
Application Protocols
Extracting Total RNA
Application Protocols
Immunofluorescent Labeling of iCell Cardiomyocytes
Application Protocols
Measuring Cardiac Activity: Impedance Detection with xCELLigence RTCA Cardio System
Application Protocols
Measuring Cardiac Activity: Intracellular Calcium Flux Detection on the FLIPR Tetra System
Application Protocols
Measuring Cardiac Electrical Activity: Field Potential Detection with Axion Maestro Multielectrode Array
Application Protocols
Measuring Cardiac Electrical Activity: Field Potential Detection with Multielectrode Array
Application Protocols
Measuring Cardiac Electrical Activity: Manual Perforated Patch Clamp
Application Protocols
Modeling Cardiac Hypertrophy: Endothelin-1 Induction with ELISA Analysis
Application Protocols
Modeling Cardiac Hypertrophy: Endothelin-1 Induction with Flow Cytometry Analysis
Application Protocols
Modeling Cardiac Hypertrophy: Endothelin-1 Induction with High Content Analysis
Application Protocols
Modeling Cardiac Hypertrophy: Endothelin-1 Induction with qRT-PCR Analysis
Application Protocols
Modeling Cardiac Ischemia: Hypoxia Induction for Cardioprotection Screening
Application Protocols
Performing Bioenergetic Analysis: Seahorse Bioscience XF96 Extracellular Flux Analyzer
Application Protocols
Using Liposome-mediated Transfection for Gene Delivery
Application Protocols
Using Transfection for siRNA Delivery
USER DOCS
Biosafety Document
iCell Cardiomyocytes and iCell Cardiomyocytes2 Biosafety Document
Datasheet
iCell Cardiomyocytes
Safety Data Sheet
iCell Cardiomyocytes Maintenance Medium, iCell Cardiomyocytes Plating Medium Safety Data Sheet - Asia
Safety Data Sheet
iCell Cardiomyocytes Maintenance Medium, iCell Cardiomyocytes Plating Medium Safety Data Sheet - Europe
Safety Data Sheet
iCell Cardiomyocytes Maintenance Medium, iCell Cardiomyocytes Plating Medium Safety Data Sheet - Germany
Safety Data Sheet
iCell Cardiomyocytes Maintenance Medium, iCell Cardiomyocytes Plating Medium Safety Data Sheet - North America
Safety Data Sheet
iCell Cell-Based Products Safety Data Sheet - Asia
Safety Data Sheet
iCell Cell-Based Products Safety Data Sheet - Germany
Safety Data Sheet
iCell Cell-Based Products Safety Data Sheet - North America
User's Guides
iCell Cardiomyocytes
Performance Data
iCell Cardiomyocytes are a High-Purity Cardiac Population.
Flow cytometry analysis and immunostaining show that iCell Cardiomyocytes are typically >95% cTNT+) with intact sarcomeric myofilament organization. (Data were adapted from Kattman et al., 2011).
Figure 1: iCell Cardiomyocytes are a High-Purity Cardiac Population.
Figure 2: iCell Cardiomyocytes Recapitulate Native Cardiac Function
iCell Cardiomyocytes Recapitulate Native Cardiac Function
iCell Cardiomyocytes form a spontaneously beating monolayer within 7 days. iCell Cardiomyocytes contain the expected human cardiac ionic currents and show the expected effects when exposed to compounds including ion channel blockers. (Data were adapted from Ma et al., 2011).
iCell Cardiomyocytes have Appropriate Sarcomeric Organization, Calcium Handling and Intact Excitation-Contraction Coupling.
Their electrophysiological activity can be pharmacologically modulated and quantified by recording the electrical activity using a multielectrode array (MEA). The field potential duration (FPD) increases or decreases as expected when exposed to ion channel-blocking drugs for key cardiac channels.
Figure 3: iCell Cardiomyocytes have Appropriate Sarcomeric Organization, Calcium Handling and Intact Excitation-Contraction Coupling.
Figure 4: Intracellular Calcium (Ca2+) Handling Provides a High-throughput Biomarker for Ion Channel and GPCR Activity.
Intracellular Calcium (Ca2+) Handling Provides a High-throughput Biomarker for Ion Channel and GPCR Activity.
Electrical activity at the membrane is controlled by ion channels and GPCRs. This activity drives intracellular Ca2+ handling. Panel A shows representative calcium handling waveforms at baseline. Panels B and C show the effect of the GPCR β-adrenergic agonist ISO or the IKr channel blocker E-4031, respectively.
Product Highlights
Cardiotoxicity Assessment
Retrospective analyses were leveraged to uncover previously undetected mechanisms of drug-induced cardiotoxicity and provide relevant data in support of Investigational New Drug (IND) applications (Talbert et al., 2014, Cameron et al., 2013, Doherty et al., 2013, Rana et al., 2012, Cohen et al., 2011).
Regenerative Medicine
iCell Cardiomyocytes are compatible with bioengineered, implantable scaffolds used as a model for heart repair following myocardial infarction (Richards et al., 2017, Beauchamp et al., 2015, Holt-Casper et al., 2015, Lancaster et al., 2012).
Calcium Signaling
Simultaneously assess effects on electrical and calcium signals measurements using iCell Cardiomyocytes with FDSS ( Bedut et al., 2016) or FLIPR platforms.
Cardiac Hypertrophy Studies
iCell Cardiomyocytes can detect known and novel biomarkers and identify new targets for drug discovery and therapeutics research (Jones et al., 2015, Drawnel et al., 2014, Arrarwal et al., 2014,, Traister et al., 2014, Zhi et al., 2012).
Arrhythmia Testing
iCell Cardiomyocytes are changing regulatory paradigms by providing a highly predictive model for detecting drug-induced arrhythmia (Guo et al., 2018).